Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03695081
Other study ID # 59475
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 3, 2018
Est. completion date June 28, 2023

Study information

Verified date June 2023
Source Sykehuset i Vestfold HF
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date June 28, 2023
Est. primary completion date June 15, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hip fracture patients in Vestfold county, Norway Exclusion Criteria: - Patients under 18 years - Terminally ill - Hip fracture patients who do not follow the standardized patient pathway at Vestfold Regional Hospital - Patients who do not consent to be included in the study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Patient Pathway Pharmacist intervention
Medication reconciliation at admission to hospital Medication review post surgery Optimised list of drugs in the discharge summary, in accordance with hospital procedures Medication reconciliation, six weeks after discharge Medication review, six weeks after discharge

Locations

Country Name City State
Norway Vestfold Hospital Trust Tønsberg

Sponsors (2)

Lead Sponsor Collaborator
Sykehuset i Vestfold HF Hospital Pharmacy Enterprise, South Eastern Norway

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Experience of current practice A questionnaire will be distributed to all health care professionals involved in the treatment of hip fracture patients Prior to or during the early start of the intervention
Other Experience of patient pathway pharmacist Focus groups or semi-structured interviews will be performed to assess the advantages and/or disadvantages of introducing a patient pathway pharmacist. Within three months after last included patient
Primary Discharge summary score In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program At discharge (estimated five days after fracture/inclusion)
Primary Admission summary score In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note. At hospital admission (estimated to be within 24 hours after fracture)
Primary Discharge summaries written in accordance with procedure In the discharge summary, the section describing drugs should be in accordance with procedure. At discharge (estimated five days after fracture/inclusion)
Primary Number of inappropriate drugs at discharge After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list). During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion)
Secondary Readmission Patients who are readmitted to hospital is quantified 30 days after discharge
Secondary Readmission Patients who are readmitted to hospital is quantified 90 days after discharge
Secondary Death The number patients who dies is quantified 30 days after discharge
Secondary Death The number of patients who dies is quantified 90 days after discharge
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2